Baricitinib for the treatment of rheumatoid arthritis
Rheumatoid arthritis (RA) is a common inflammatory disease with several implications on health, disability and economy. Conventional treatment for RA centers on anti-inflammatory drugs and specific targeting of tumor necrosis factor (TNF-) and interleukin 6 (IL-6). Baricitinib is a novel, Food an...
Guardado en:
Autores principales: | Ivan Urits, Jacob Israel, Hayk Hakobyan, George Yusin, Grace Lassiter, Nathan Fackler, Amnon A. Berger, Hisham Kassem, Alan Kaye, Omar Viswanath |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/efa1b6f0f94641f0bc847beee18fbe9b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Miguel Nogueira, et al.
Publicado: (2021) -
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
por: Ly K, et al.
Publicado: (2019) -
Management of Rheumatoid Arthritis: An Overview
por: Andrei-Flavius Radu, et al.
Publicado: (2021) -
Tofacitinib en el tratamiento de la colitis ulcerosa: casos clínicos
por: Quera,Rodrigo, et al.
Publicado: (2020) -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study
por: Gordon D, et al.
Publicado: (2021)